- NervGen Pharma (NGEN) has appointed Dr. Daniel Mikol to its senior management team as Chief Medical Officer
- Dr. Mikol is a board certified neurologist with 13 years of pharmaceutical industry experience focused on neurodegenerative diseases
- He he will oversee NervGen’s medical and clinical activities, with a primary focus on NervGen’s lead product, NVG-291
- NervGen Pharma is a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases
- NervGen Pharma (NGEN) is down 0.66 per cent and is trading at $1.50 per share
NervGen Pharma (NGEN) has appointed Dr. Daniel Mikol to its senior management team as Chief Medical Officer.
Dr. Mikol, a veteran of the pharmaceutical industry, currently serves as Executive Medical Director at Amgen, and will start as CMO of NervGen on May 5, 2021.
As CMO, he will oversee NervGen’s medical and clinical activities, with a primary focus on NervGen’s lead product, NVG-291, which is being developed to treat multiple sclerosis, Alzheimer’s disease and spinal cord injury.
Paul Brennan, President and CEO of NervGen, commented,
“Dan’s expertise in neurology and neuroscience research, and the clinical development of neuroscience products in the pharmaceutical industry will be an immeasurable benefit to NervGen as we start our clinical trials.”
Dr. Mikol is a board-certified neurologist with 13 years of pharmaceutical industry experience focused on neurodegenerative diseases.
“What has drawn me to NervGen is the large extent of scientific data supporting the importance of this target in inhibiting nerve repair and the opportunity to lead the clinical development of a program and platform that can be truly revolutionary for treating patients with nerve damage,” he commented.
He added,
“The potential for NVG-291 to help patients with multiple sclerosis, Alzheimer’s disease and spinal cord injury is truly inspiring, and I look forward to playing a lead role in making this happen.”
NervGen Pharma is a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases.
NervGen Pharma (NGEN) is down 0.66 per cent and is trading at $1.50 per share as of 9:52 am ET.
